Proteomic indicators of metabolic health in diabetes and social deprivation


  • Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives.
  • Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignal® Tests (SST)
  • We applied 11 SSTs to the Psychological, Social, and Biological Determinants of Ill Health (PsoBid) cohort to
    characterize the association between cardiometabolic health and social deprivation and diabetes.


  • PsoBid is a cross-sectional study that recruited participants from socioeconomically deprived and affluent areas of Glasgow, Scotland, to identify relevant health disparities.1
  • The cohort has similar age ranges and equal proportions of male and female in the affluent and deprived group.
  • We used generalized linear model regression analyses to compare means between SSTs (standardized to z-scores) and socioeconomic status and prevalent diabetes and to test for interactions.


  • These results demonstrate that participants with diabetes and SED have proteomic phenotypes consistent with worsened cardiometabolic health compared to participants without diabetes or SED.
  • SED is associated with worse predicted cardiovascular risk in patients with diabetes.
  • While the number of participants with diabetes was small (n = 27, 5.3%), we were able to identify differences in proteomic phenotypes compared to participants without diabetes.
  • Proteomics may be useful in identifying and monitoring the health effects of diabetes and SED or the impact of relevant interventions.


Missy Simpson1
Paul Welsh2
Chris Packard2
Rachel Ostroff1
Stephen Williams1
Naveed Sattar2

1SomaLogic Operating Co., Inc., Boulder, CO, USA
2School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland

Learn more by downloading this poster now

Download poster

Share with colleagues

More posters

PosterQuantitative immunology protein panel built on the SomaScan Assay platform

The SomaScan® assay is a highly multiplexed proteomic assay that uses SOMAmer® reagents to detect proteins in various biological samples. The latest version of the SomaScan assay allows researchers to measure over 11,000 proteins in human blood. The SomaScan assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer reagent abundance quantified using DNA microarrays.

Learn more

PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points

The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.

Learn more

PosterStatin signature: using proteomics to detect pharmacological fingerprints

Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).

Learn more

Explore posters in our interactive viewer